Vantage Biosciences
Clinical-stage biotechnology company headquartered in London developing orally administered small-molecule inhibitors of AOC-3 to treat inflammatory neurovascular diseases, with a lead programme in Phase 2 for non-proliferative diabetic retinopathy and earlier-stage programmes in liver disease (MASH, PSC). The company is backed by ALSA Ventures and runs multi-regional clinical studies.
Industries
Nr. of Employees
small (1-50)
Vantage Biosciences
Patents
Products
Oral AOC-3 inhibitor (oruvestat / VX-01)
Investigational, orally administered small-molecule inhibitor of AOC-3 developed to reduce leukocyte recruitment and oxidative deamination in neurovascular tissues; being evaluated in Phase 2 for non-proliferative diabetic retinopathy and studied preclinically for liver diseases (MASH, PSC).
Oral AOC-3 inhibitor (oruvestat / VX-01)
Investigational, orally administered small-molecule inhibitor of AOC-3 developed to reduce leukocyte recruitment and oxidative deamination in neurovascular tissues; being evaluated in Phase 2 for non-proliferative diabetic retinopathy and studied preclinically for liver diseases (MASH, PSC).
Expertise Areas
- Clinical trial management
- Translational drug discovery for AOC-3
- Oral small-molecule therapeutics
- Ophthalmology therapeutics (diabetic retinopathy)
Key Technologies
- AOC-3 (amine oxidase) targeting
- Oral small-molecule inhibitors
- Preclinical animal models for retinal and liver disease
- Biomarker assays (soluble AOC-3, liver injury markers)
News & Updates
Announcement of company launch and acquisition of a lead oral AOC-3 inhibitor programme; Phase 2 planned to commence mid-2024.
Participation and presentation on development of an oral therapy for non-proliferative diabetic retinopathy at OIS (December 2023).
Announcement that the first patient was dosed in the Phase 2 multi-center study evaluating the oral AOC-3 inhibitor for non-proliferative diabetic retinopathy.
World Health Organization assigned an International Nonproprietary Name (INN) to the company’s investigational oral small molecule formerly referenced by a development code.
Company announced completion of patient enrollment for the Phase 2 SeeClear (VX01-DR-201) study evaluating the oral AOC-3 inhibitor in moderate-to-severe NPDR; topline data expected Q4 2027.
Announcement of company launch and acquisition of a lead oral AOC-3 inhibitor programme; Phase 2 planned to commence mid-2024.
Participation and presentation on development of an oral therapy for non-proliferative diabetic retinopathy at OIS (December 2023).
Announcement that the first patient was dosed in the Phase 2 multi-center study evaluating the oral AOC-3 inhibitor for non-proliferative diabetic retinopathy.
World Health Organization assigned an International Nonproprietary Name (INN) to the company’s investigational oral small molecule formerly referenced by a development code.
Company announced completion of patient enrollment for the Phase 2 SeeClear (VX01-DR-201) study evaluating the oral AOC-3 inhibitor in moderate-to-severe NPDR; topline data expected Q4 2027.